T1	PROC 44 58	Estudio fase 3
T2	CHEM 62 71	nivolumab
#1	AnnotatorNotes T2	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T3	PROC 75 86	monoterapia
#2	AnnotatorNotes T3	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T4	CHEM 89 98	nivolumab
#3	AnnotatorNotes T4	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T5	CHEM 113 123	ipilimumab
#4	AnnotatorNotes T5	C1367202; ipilimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T6	CHEM 133 143	ipilimumab
#5	AnnotatorNotes T6	C1367202; ipilimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T7	PROC 147 158	monoterapia
#6	AnnotatorNotes T7	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T8	DISO 174 182	melanoma
#7	AnnotatorNotes T8	C0025202; melanoma; Neoplastic Process
T9	PROC 254 295	Estudio fase 3, aleatorizado, doble ciego
T10	CHEM 300 309	nivolumab
#8	AnnotatorNotes T10	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T11	PROC 313 324	monoterapia
#9	AnnotatorNotes T11	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T12	CHEM 327 336	nivolumab
#10	AnnotatorNotes T12	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T13	CHEM 351 361	ipilimumab
#11	AnnotatorNotes T13	C1367202; ipilimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T14	CHEM 371 381	ipilimumab
#12	AnnotatorNotes T14	C1367202; ipilimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T15	PROC 385 396	monoterapia
#13	AnnotatorNotes T15	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T16	DISO 412 420	melanoma
#14	AnnotatorNotes T16	C0025202; melanoma; Neoplastic Process
T17	ANAT 497 503	sangre
#15	AnnotatorNotes T17	C0005767; Blood; Body Substance
T18	DISO 579 587	Melanoma
#16	AnnotatorNotes T18	C0025202; melanoma; Neoplastic Process
T19	DISO 666 674	Melanoma
#17	AnnotatorNotes T19	C0025202; melanoma; Neoplastic Process
T20	PROC 810 821	tratamiento
#18	AnnotatorNotes T20	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T21	PROC 843 871	terapia oncológica sistémica
T22	DISO 886 894	melanoma
#19	AnnotatorNotes T22	C0025202; melanoma; Neoplastic Process
T23	DISO 925 943	Enfermedad medible
#20	AnnotatorNotes T23	C1513041; Measurable Disease; Disease or Syndrome
T24	PROC 958 960	RM
#21	AnnotatorNotes T24	C0024485; Magnetic Resonance Imaging; Diagnostic Procedure
T25	ANAT 1012 1026	tejido tumoral
T26	DISO 1079 1089	enfermedad
#22	AnnotatorNotes T26	C0012634; Disease; Disease or Syndrome
T27	PROC 1098 1123	análisis de biomarcadores
T28	DISO 1175 1196	Metástasis cerebrales
#23	AnnotatorNotes T28	C0220650; Metastatic malignant neoplasm to brain; Neoplastic Process | C0555278; Cerebral metastasis; Neoplastic Process
T29	DISO 1207 1232	metástasis leptomeníngeas
#24	AnnotatorNotes T29	C1704231; Metastatic Malignant Neoplasm to the Leptomeninges; Neoplastic Process
T30	DISO 1237 1252	Melanoma ocular
#25	AnnotatorNotes T30	C0558356; Malignant melanoma of eye; Neoplastic Process
T31	DISO 1268 1294	enfermedad autoinmunitaria
#26	AnnotatorNotes T31	C0004364; Autoimmune Diseases; Disease or Syndrome
T32	PROC 1365 1407	tratamiento sistémico con corticosteroides
T33	CHEM 1391 1407	corticosteroides
#27	AnnotatorNotes T33	C0001617; Adrenal Cortex Hormones; Hormone · Organic Chemical · Pharmacologic Substance
T34	CHEM 1420 1430	prednisona
#28	AnnotatorNotes T34	C0032952; prednisone; Hormone · Organic Chemical · Pharmacologic Substance
T35	CHEM 1461 1490	medicamentos inmunosupresores
T36	CHEM 1545 1552	fármaco
#29	AnnotatorNotes T36	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T37	CHEM 1578 1588	esteroides
#30	AnnotatorNotes T37	C0038317; Steroids; Organic Chemical · Pharmacologic Substance
T38	ANAT 1631 1642	suprarrenal
#31	AnnotatorNotes T38	C0001625; Adrenal Glands; Body Part, Organ, or Organ Component
T39	CHEM 1661 1671	prednisona
#32	AnnotatorNotes T39	C0032952; prednisone; Hormone · Organic Chemical · Pharmacologic Substance
T40	DISO 1702 1728	enfermedad autoinmunitaria
#33	AnnotatorNotes T40	C0004364; Autoimmune Diseases; Disease or Syndrome
T41	PROC 1739 1750	Tratamiento
#34	AnnotatorNotes T41	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T42	CHEM 1765 1785	anticuerpo anti-PD-1
T43	CHEM 1787 1797	anti-PD-L1
T44	CHEM 1799 1809	anti-PD-L2
T45	CHEM 1812 1823	anti-CTLA-4
T46	CHEM 1841 1851	anticuerpo
#35	AnnotatorNotes T46	C0003241; Antibodies; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T47	CHEM 1854 1949	fármaco dirigido específicamente frente a la coestimulación de las vías de control inmunitarias
#36	AnnotatorNotes T47	C3192215; Selective T Cell Costimulation Blocker; Pharmacologic Substance (?)
T48	DISO 197 208	metastásico
#37	AnnotatorNotes T48	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T49	DISO 435 446	metastásico
#38	AnnotatorNotes T49	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T50	PROC 486 503	muestra de sangre
#39	AnnotatorNotes T50	C0005834; Collection of blood specimen for laboratory procedure; Diagnostic Procedure | C1277698; Blood sample taken; Laboratory Procedure
T51	DISO 602 613	metastásico
#40	AnnotatorNotes T51	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T52	PROC 450 457	tratado
#41	AnnotatorNotes T52	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T53	PROC 617 624	tratado
#42	AnnotatorNotes T53	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T54	DISO 909 920	metastásico
#43	AnnotatorNotes T54	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T55	PROC 953 955	TC
#44	AnnotatorNotes T55	C0040405; X-Ray Computed Tomography; Diagnostic Procedure
T56	DISO 1019 1026	tumoral
#45	AnnotatorNotes T56	C0006826; Malignant Neoplasms; Neoplastic Process | C0027651; Neoplasms; Neoplastic Process | C1882062; Neoplastic disease; Neoplastic Process
T57	DISO 1061 1072	metastásica
#46	AnnotatorNotes T57	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T58	ANAT 1186 1196	cerebrales
#47	AnnotatorNotes T58	C0242202; Cerebrum; Body Part, Organ, or Organ Component | C1269537; Entire brain; Body Part, Organ, or Organ Component | C1280654; Entire cerebrum; Body Part, Organ, or Organ Component
T59	ANAT 1218 1232	leptomeníngeas
#48	AnnotatorNotes T59	C0228126; Leptomeninges; Body Part, Organ, or Organ Component | C1284563; Entire leptomeninges; Body Part, Organ, or Organ Component
T60	ANAT 1246 1252	ocular
#49	AnnotatorNotes T60	C0015392; Eye; Body Part, Organ, or Organ Component | C1280202; Entire eye; Body Part, Organ, or Organ Component
T61	PROC 1526 1552	administración del fármaco
#50	AnnotatorNotes T61	C3469597; Administration of medication; Therapeutic or Preventive Procedure
T62	PROC 212 219	tratado
#51	AnnotatorNotes T62	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T63	Date 12 16	2012
T64	LIVB 162 169	sujetos
#52	AnnotatorNotes T64	C0681850; Study Subject; Group
T65	Neg_cue 209 211	no
T66	LIVB 400 407	sujetos
#53	AnnotatorNotes T66	C0681850; Study Subject; Group
T67	Neg_cue 447 449	no
T68	Neg_cue 614 616	no
T69	PROC 769 792	estadificación del AJCC
#54	AnnotatorNotes T69	C1971458; American Joint Committee on Cancer (AJCC) stage documented and reviewed (ONC); Health Care Activity
T70	LIVB 796 805	Pacientes
#55	AnnotatorNotes T70	C0030705; Patients; Patient or Disabled Group
T71	Neg_cue 806 809	sin
T72	Neg_cue 839 842	sin
T73	LIVB 1256 1263	Sujetos
#56	AnnotatorNotes T73	C0681850; Study Subject; Group
T74	Spec_cue 1314 1324	sospechada
T75	LIVB 1329 1336	Sujetos
#57	AnnotatorNotes T75	C0681850; Study Subject; Group
T76	Dose 1409 1416	> 10 mg
T77	Frequency 1431 1437	al día
T78	Duration 1506 1513	14 días
T79	Route 1589 1598	inhalados
#58	AnnotatorNotes T79	C0205535; Inhalation Route of Drug Administration; Functional Concept
T80	Route 1601 1608	tópicos
#59	AnnotatorNotes T80	C1522168; Topical Route of Drug Administration; Functional Concept
T81	Dose 1643 1650	> 10 mg
T82	Frequency 1651 1657	al día
T83	Neg_cue 1690 1701	ausencia de
T86	Date 545 556	19-Mar-2013
T84	PROC 686 702	histológicamente
#60	AnnotatorNotes T84	C0344441; Histology Procedure; Laboratory Procedure
T85	PROC 509 524	farmacogenética
#61	AnnotatorNotes T85	C3494710; Pharmacogenetic consultation; Health Care Activity (?)
A1	Assertion T62 Negated
A2	Assertion T52 Negated
A3	Assertion T53 Negated
A4	Assertion T20 Negated
A5	Assertion T21 Negated
A6	Assertion T31 Speculated
A7	Assertion T40 Negated
A8	Status T53 History_of
A9	Status T52 History_of
A10	Status T62 History_of
A11	Status T20 History_of
A12	Status T21 History_of
A13	Status T41 History_of
A14	Status T42 History_of
A15	Status T43 History_of
A16	Status T44 History_of
A17	Status T45 History_of
A18	Status T46 History_of
A19	Status T47 History_of
A20	Status T31 History_of
#62	AnnotatorNotes T27	C1879847; Biomarker Analysis; Laboratory Procedure
#63	AnnotatorNotes T35	C0021081; Immunosuppressive Agents; Immunologic Factor · Pharmacologic Substance
#64	AnnotatorNotes T9	C0282461; Phase 3 Clinical Trials; Research Activity + C0034656; Randomization; Research Activity + C0013072; Double-Blind Method; Research Activity
#65	AnnotatorNotes T1	C0282461; Phase 3 Clinical Trials; Research Activity
#66	AnnotatorNotes T25	C0475358; Tumor tissue sample; Tissue
#67	AnnotatorNotes T32	C4053960; Systemic Corticosteroid Therapy; Therapeutic or Preventive Procedure 
#68	AnnotatorNotes T42	C4289971; Anti-PD-L1 Monoclonal Antibody; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
#69	AnnotatorNotes T43	C4289971; Anti-PD-L1 Monoclonal Antibody; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
#70	AnnotatorNotes T45	C4289973; Anti-CTLA-4 Monoclonal Antibody; Amino Acid, Peptide, or Protein
R1	Negation Arg1:T71 Arg2:T20	
R2	Negation Arg1:T72 Arg2:T21	
R3	Speculation Arg1:T74 Arg2:T31	
R4	Negation Arg1:T83 Arg2:T40	
T87	Quantifier_or_Qualifier 1729 1735	activa
A21	Assertion T87 Negated
#71	AnnotatorNotes T87	C0679217; Active State; Idea or Concept
R5	Has_Quantifier_or_Qualifier Arg1:T40 Arg2:T87	
R6	Used_for Arg1:T2 Arg2:T3	
R7	Combined_with Arg1:T4 Arg2:T5	
R8	Used_for Arg1:T6 Arg2:T7	
R9	Experiences Arg1:T64 Arg2:T2	
R10	Experiences Arg1:T64 Arg2:T4	
R11	Experiences Arg1:T64 Arg2:T6	
R12	Experiences Arg1:T64 Arg2:T8	
R13	Before Arg1:T8 Arg2:T48	
R14	Experiences Arg1:T64 Arg2:T48	
R15	Negation Arg1:T65 Arg2:T62	
T88	Observation 183 194	irresecable
#72	AnnotatorNotes T88	C4039777; Tumor surgically unresectable; Finding
R16	Has_Quantifier_or_Qualifier Arg1:T8 Arg2:T88	
R17	Used_for Arg1:T10 Arg2:T11	
R18	Combined_with Arg1:T12 Arg2:T13	
R19	Used_for Arg1:T14 Arg2:T15	
R20	Experiences Arg1:T66 Arg2:T10	
R21	Experiences Arg1:T66 Arg2:T12	
R22	Experiences Arg1:T66 Arg2:T14	
R23	Experiences Arg1:T66 Arg2:T16	
R24	Experiences Arg1:T66 Arg2:T49	
R25	Before Arg1:T16 Arg2:T49	
T89	Observation 421 432	irresecable
#73	AnnotatorNotes T89	C4039777; Tumor surgically unresectable; Finding
R26	Has_Quantifier_or_Qualifier Arg1:T16 Arg2:T89	
R27	Experiences Arg1:T66 Arg2:T52	
R28	Negation Arg1:T67 Arg2:T52	
R29	Experiences Arg1:T64 Arg2:T62	
R30	Before Arg1:T50 Arg2:T85	
T90	Observation 588 599	irresecable
#74	AnnotatorNotes T90	C4039777; Tumor surgically unresectable; Finding
R31	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T90	
R32	Before Arg1:T18 Arg2:T51	
R33	Negation Arg1:T68 Arg2:T53	
T91	Result_or_Value 706 717	estadio III
T92	Observation 719 730	irresecable
#75	AnnotatorNotes T92	C4039777; Tumor surgically unresectable; Finding
R35	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T92	
T93	Result_or_Value 737 747	estadio IV
R39	Has_Result_or_Value Arg1:T69 Arg2:T91	
R40	Has_Result_or_Value Arg1:T69 Arg2:T93	
R36	Experiences Arg1:T70 Arg2:T20	
T94	Observation 895 906	irresecable
#76	AnnotatorNotes T94	C4039777; Tumor surgically unresectable; Finding
R37	Has_Quantifier_or_Qualifier Arg1:T22 Arg2:T94	
R41	Has_Quantifier_or_Qualifier Arg1:T22 Arg2:T54	
R42	Experiences Arg1:T70 Arg2:T22	
R43	Before Arg1:T70 Arg2:T54	
T95	CONC 981 991	RECIST 1.1
#77	AnnotatorNotes T95	C4086827; Response Evaluation Criteria in Solid Tumors Version 1.1; Intellectual Product
R47	Location_of Arg1:T25 Arg2:T27	
R48	Has_Quantifier_or_Qualifier Arg1:T56 Arg2:T57	
T96	Observation 1047 1058	irresecable
#78	AnnotatorNotes T96	C4039777; Tumor surgically unresectable; Finding
R49	Has_Quantifier_or_Qualifier Arg1:T25 Arg2:T96	
R50	Location_of Arg1:T58 Arg2:T28	
R51	Location_of Arg1:T59 Arg2:T29	
R52	Location_of Arg1:T25 Arg2:T57	
T97	CONC 1141 1145	ECOG
#79	AnnotatorNotes T97	C1520224; ECOG performance status; Intellectual Product
T98	Result_or_Value 1131 1136	0 ó 1
R53	Has_Result_or_Value Arg1:T97 Arg2:T98	
T99	Quantifier_or_Qualifier 1197 1204	activas
#80	AnnotatorNotes T99	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R54	Has_Quantifier_or_Qualifier Arg1:T28 Arg2:T99	
R55	Location_of Arg1:T60 Arg2:T30	
R56	Experiences Arg1:T73 Arg2:T31	
T100	Quantifier_or_Qualifier 1295 1301	activa
#81	AnnotatorNotes T100	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R57	Has_Quantifier_or_Qualifier Arg1:T31 Arg2:T100	
R58	Experiences Arg1:T75 Arg2:T32	
R59	Used_for Arg1:T33 Arg2:T32	
R60	Has_Dose_or_Strength Arg1:T33 Arg2:T76	
R61	Has_Frequency Arg1:T33 Arg2:T77	
R62	Has_Frequency Arg1:T34 Arg2:T77	
R63	Has_Dose_or_Strength Arg1:T34 Arg2:T76	
T101	CONC 1420 1430;1440 1451	prednisona equivalente
R64	Used_for Arg1:T34 Arg2:T32	
R65	Experiences Arg1:T75 Arg2:T35	
R66	Overlap Arg1:T35 Arg2:T78	
R67	Before Arg1:T35 Arg2:T61	
R68	Overlap Arg1:T33 Arg2:T78	
R69	Overlap Arg1:T34 Arg2:T78	
R70	Before Arg1:T32 Arg2:T61	
R71	Used_for Arg1:T36 Arg2:T61	
R72	Before Arg1:T34 Arg2:T61	
R73	Experiences Arg1:T75 Arg2:T61	
R74	Has_Route_or_Mode Arg1:T37 Arg2:T79	
R75	Has_Route_or_Mode Arg1:T37 Arg2:T80	
R76	Has_Dose_or_Strength Arg1:T37 Arg2:T81	
R77	Has_Frequency Arg1:T37 Arg2:T82	
R78	Has_Frequency Arg1:T39 Arg2:T82	
R79	Has_Dose_or_Strength Arg1:T39 Arg2:T81	
T102	CONC 1661 1671;1674 1686	prednisona equivalentes
R82	Used_for Arg1:T42 Arg2:T41	
R83	Used_for Arg1:T43 Arg2:T41	
R84	Used_for Arg1:T44 Arg2:T41	
R85	Used_for Arg1:T45 Arg2:T41	
R86	Used_for Arg1:T46 Arg2:T41	
R87	Used_for Arg1:T47 Arg2:T41	
R34	Experiences Arg1:T70 Arg2:T54	
R38	Negation Arg1:T83 Arg2:T87	
R44	Experiences Arg1:T70 Arg2:T21	
T103	CONC 1566 1577	Se permiten
A22	Experiencer T64 Patient
A23	Experiencer T66 Patient
A24	Experiencer T70 Patient
A25	Experiencer T73 Patient
A26	Experiencer T75 Patient
